In his first investor update as GSK’s CEO, Luke Miels defined a core of his vision for the company’s next chapter: “We need to be more product-centric as a company.” Being product-centric means ...

In GSK’s first quarter under Luke Miels as CEO, the company’s flagship shingles vaccine, Shingrix, set a new quarterly sales record, while its closely watched asthma launch, Exdensur, showed “early ...

The impact of regime change at GSK is finally being seen. The Emma Walmsley period focused on sorting out the structure of the enterprise, selling off consumer healthcare to focus on core R&D, ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Half a year into taking ...

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. Miels—who served as GSK’s ...

LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next ‌phase of growth through a sharper ...

LONDON (Reuters) - Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

Emma Walmsley has served as CEO of GlaxoSmithKline since 2017. From the Philadelphia Business Journal. GSK is making a change at the top. The London-based Big Pharma company, which has major ...